Hospira (FRA:HOS) 5-Year Yield-on-Cost % : 0.00 (As of May. 05, 2024)

View and export this data going back to . Start your Free Trial

What is Hospira 5-Year Yield-on-Cost %?

Hospira's yield on cost for the quarter that ended in Jun. 2015 was 0.00.

The historical rank and industry rank for Hospira's 5-Year Yield-on-Cost % or its related term are showing as below:

FRA:HOS's 5-Year Yield-on-Cost % is not ranked ^*
in the Drug Manufacturers industry.
Industry Median: 2.145
* Ranked among companies with meaningful 5-Year Yield-on-Cost % only.

Competitive Comparison of Hospira's 5-Year Yield-on-Cost %

For the Drug Manufacturers - Specialty & Generic subindustry, Hospira's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Hospira's 5-Year Yield-on-Cost % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Hospira's 5-Year Yield-on-Cost % distribution charts can be found below:

* The bar in red indicates where Hospira's 5-Year Yield-on-Cost % falls into.

Hospira 5-Year Yield-on-Cost % Calculation

Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.

Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.

Therefore, Yield-on-Cost of Hospira is calculated as

Yield-on-Cost

Dividend Yield %

Dividend Growth Rate)^5

Hospira (FRA:HOS) 5-Year Yield-on-Cost % Explanation

Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.

Hospira 5-Year Yield-on-Cost % Related Terms

Thank you for viewing the detailed overview of Hospira's 5-Year Yield-on-Cost % provided by GuruFocus.com. Please click on the following links to see related term pages.

Hospira (FRA:HOS) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Hospira Inc (FRA:HOS) » Definitions » 5-Year Yield-on-Cost %

Comparable Companies

Traded in Other Exchanges

N/A

Address

Website

http://www.hospira.com

Hospira Inc was incorporated in Delaware on September 16, 2003.Â The Company is a provider of injectable drugs and infusion technologies, and is also engaged in developing, manufacturing, marketing and distribution. Its portfolio includes generic acute-care and oncology injectables, biosimilars, and integrated infusion therapy and medication management products. Its portfolio of products is used by hospitals and alternate site providers, such as clinics, home healthcare providers and long-term care facilities. The Company's business segments are Specialty Injectable Pharmaceuticals, Medication Management and Other Pharmaceuticals. Specialty Injectable Pharmaceuticals consists of generic injectable pharmaceuticals products. Generic injectable pharmaceuticals provide customers with a lower-cost alternative to branded products when associated patent protection expires, when patents are declared invalid, or when the generic products do not infringe the patents of others. Our generic injectable pharmaceuticals are sold in therapeutic areas including analgesia, anesthesia, anti-infectives, cardiovascular, oncology, and other. Medication Management offer the Hospira MedNet safety software system, which is designed for hospitals to customize intravenous drug dosage limits and track drug delivery to prevent medication errors. The wireless network version of the Hospira MedNet system establishes real-time send-and-receive capability and can interface with select hospital and pharmacy information systems. Other Pharmaceuticals primarily consists of large volume I.V. solutions, nutritionals and contract manufacturing services. We offer infusion therapy solutions and related supplies that include I.V. solutions for general use, I.V. nutrition products, and solutions for washing and cleansing of wounds or surgical sites. The Company's primary customers include hospitals, wholesalers, integrated delivery networks and alternate site facilities. Its competitors include Baxter International Inc.; Becton, Dickinson and Company; Fresenius Kabi AG; Mallinckrodt plc; Mylan Inc; Par Pharmaceuticals Companies, Inc.; Pfizer Inc.; Sandoz; Sanofi S.A. and Teva Pharmaceuticals, Aspen Medical; Fresenius Kabi; Pfizer; Sandoz and a number of smaller competitors and the originator companies. The Company's operations and business activities are subject to extensive legal and regulatory requirements that are enforced by numerous governmental agencies in the countries in which it do business.

Hospira (FRA:HOS) Headlines

No Headlines